Low-Dose Naltrexone for Chronic Pain: Could LDN Be Right for You?
Living with persistent pain can be exhausting, especially when symptoms interfere with sleep, energy, concentration, work, and daily activities.
Low-dose naltrexone, commonly known as LDN, has attracted attention as a potential option for certain chronic pain conditions, including fibromyalgia. Some studies suggest that selected patients may experience symptom improvement, but LDN is not a universal solution and the evidence is not equally strong for every condition.
So, how do you know whether LDN is worth discussing with a healthcare provider?
The answer depends on your diagnosis, medications, opioid exposure, overall health, treatment goals, and the quality of evidence for your particular condition.
What Is Low-Dose Naltrexone?
Naltrexone is a prescription opioid antagonist. At its FDA-approved oral dose, it is used as part of the treatment of alcohol dependence and to block the effects of externally administered opioids.
Low-dose naltrexone refers to clinician-directed use of naltrexone at a dose below the standard FDA-approved 50 mg oral tablet. When prescribed for fibromyalgia, persistent pain, inflammatory symptoms, or similar conditions, LDN is used off-label.
Off-label prescribing is a recognized part of medical practice. However, it means the FDA has not approved naltrexone as safe and effective for that specific condition.
If you are new to LDN, start with our introductory guide:
What Is Low-Dose Naltrexone? Uses, Evidence, and Safety
Why Is LDN Being Studied for Chronic Pain?
Persistent pain is not always caused by ongoing tissue damage. In some conditions, the nervous system may become increasingly sensitive to pain signals. This is sometimes called central sensitization or centralized pain.
Researchers have proposed that low-dose naltrexone may influence:
- Pain processing
- Opioid-receptor signaling
- Immune signaling within the nervous system
- Microglial activity
- Certain inflammatory pathways
These proposed mechanisms help explain why LDN is being studied, but a plausible mechanism does not prove that a treatment will work for an individual patient.
The more important question is what controlled clinical studies have found.
Where Is the Evidence for LDN Strongest?
Fibromyalgia
Fibromyalgia is currently one of the most studied chronic pain conditions involving LDN.
An early randomized crossover study involving 31 women with fibromyalgia reported a greater reduction in baseline pain during LDN treatment than during placebo treatment. The researchers appropriately described the findings as preliminary. Review the study on PubMed.
More recent randomized trials and systematic reviews have produced mixed findings. Some analyses suggest that LDN may improve pain compared with placebo, while other research has not found a clinically meaningful benefit for every outcome or population.
A 2025 systematic review and meta-analysis reported improvement in fibromyalgia pain compared with placebo. However, the available trials remain relatively small, and researchers have used different study designs, outcome measures, treatment durations, and doses.
The responsible conclusion is:
LDN may help some patients with fibromyalgia, but it has not been proven to work for everyone and more high-quality research is needed.
Centralized and persistent pain
A 2023 scoping review examining LDN for centralized pain found improvements in several patient-reported pain and functional outcomes across the available literature. However, much of the evidence came from small studies, case reports, and observational research rather than large confirmatory trials. Read the review on PubMed.
Another review described LDN as promising for conditions such as fibromyalgia and certain inflammatory pain disorders while emphasizing the need for larger and better-controlled studies. Review the chronic pain evidence.
This means LDN may be worth evaluating in selected patients, but “chronic pain” is too broad to predict whether a particular person will benefit.
Arthritis and rheumatologic conditions
Research involving rheumatoid arthritis, osteoarthritis, and other rheumatologic conditions is more limited.
A 2023 review concluded that LDN appears promising in some rheumatologic diseases but emphasized that the available data are limited. Review the rheumatology evidence.
An observational study using prescription-database information found an association between persistent LDN use and reduced use of certain other medications among patients with rheumatoid or seropositive arthritis. However, an observational association cannot prove that LDN caused the change. Read the observational study.
LDN should not be presented as a replacement for disease-modifying therapy or specialist-directed treatment.
What About LDN for Inflammation?
“Inflammation” is often used as though it were a single diagnosis. It is not.
Inflammation can result from:
- Autoimmune disease
- Infection
- Injury
- Metabolic disease
- Allergic responses
- Gastrointestinal disorders
- Numerous other medical conditions
Researchers have proposed that LDN may influence certain inflammatory and neuroimmune pathways. But that does not mean LDN has been proven to treat every condition associated with inflammation.
LDN should not be promoted as a general cure for inflammation, an “immune-system reset,” or a replacement for determining why a patient has persistent symptoms.
A proper clinical evaluation starts with the underlying condition—not the popularity of a medication.
Who Might Be Evaluated for LDN?
A clinician may consider evaluating LDN for someone who:
- Has a documented chronic pain condition
- Experiences fibromyalgia or centralized pain symptoms
- Has persistent symptoms despite other appropriate interventions
- Has a treatment goal that can be clearly identified and monitored
- Is not currently using an incompatible opioid medication
- Understands that the treatment is off-label
- Is willing to complete appropriate follow-up
- Has reviewed the potential benefits, limitations, and risks
Meeting one or more of these descriptions does not automatically make someone eligible for treatment.
A licensed clinician must determine whether LDN is medically appropriate.
Who May Not Be an Appropriate Candidate?
LDN may not be appropriate—or may require additional evaluation—for someone who:
- Currently takes an opioid pain medication
- Uses tramadol
- Takes methadone or buprenorphine
- Recently used prescription or nonprescribed opioids
- Is experiencing opioid withdrawal
- May need opioid pain management for an upcoming procedure
- Has certain liver problems
- Is pregnant, planning pregnancy, or breastfeeding
- Has a medication or health history requiring closer evaluation
This is not a complete list. Patients should provide their clinician and pharmacist with a complete medication and health history.
The Most Important LDN Safety Issue: Opioids
Naltrexone blocks opioid receptors.
According to FDA-approved naltrexone labeling, the medication is contraindicated in patients receiving opioid analgesics, patients with current physiologic opioid dependence, and patients experiencing acute opioid withdrawal.
Starting naltrexone before opioids have adequately cleared can trigger sudden withdrawal, which may be severe enough to require hospitalization.
Patients should disclose:
- Hydrocodone
- Oxycodone
- Codeine
- Morphine
- Tramadol
- Methadone
- Buprenorphine
- Opioid-containing cough medicines
- Opioid-containing diarrhea medicines
- Any nonprescribed opioid exposure
Patients should not stop an opioid or determine their own opioid-free interval. That transition must be directed by a qualified healthcare professional.
Naltrexone can also interfere with opioid pain treatment during surgery, an injury, or an emergency. Every treating provider should know when a patient is taking LDN.
Review the FDA-approved naltrexone labeling through DailyMed.
What Benefits Should Someone Realistically Track?
A treatment goal should be more specific than “feeling better.”
Depending on the condition, a clinician may ask a patient to monitor changes in:
- Average pain intensity
- Frequency of symptom flares
- Sleep quality
- Morning stiffness
- Ability to exercise or complete daily activities
- Fatigue
- Work or household function
- Use of permitted rescue medications
- Overall quality of life
Improvement does not have to mean the complete disappearance of symptoms. For some patients, a meaningful result may be better function, fewer difficult days, or improved participation in daily life.
Patients should also track new or worsening symptoms rather than assuming every change is part of an expected “adjustment.”
How Long Does LDN Take to Work?
There is no universal timeline.
LDN studies have used different treatment durations, and individual responses can vary. Some patients may notice changes earlier, while others may require a longer clinician-directed evaluation before determining whether treatment is helping.
Factors that can influence the evaluation include:
- The underlying condition
- Baseline symptom severity
- Treatment duration
- Individual tolerability
- Other medications and therapies
- Consistency of use
- How improvement is measured
A lack of immediate improvement does not justify changing the dose without guidance. It also does not mean someone should continue indefinitely without a defined reassessment plan.
The prescriber should establish:
- The symptom being targeted
- How progress will be measured
- When follow-up will occur
- What side effects should prompt contact
- When treatment should be reconsidered
What Side Effects Can Occur?
Reported effects associated with naltrexone can include:
- Nausea
- Headache
- Dizziness
- Fatigue
- Abdominal discomfort
- Sleep changes
- Vivid dreams
Not every patient experiences side effects, and an online list cannot predict an individual response.
Naltrexone labeling also contains important liver-related warnings. Patients should promptly seek medical guidance for symptoms such as persistent abdominal pain, dark urine, or yellowing of the skin or eyes.
Patients should contact their clinician when symptoms are severe, persistent, unexpected, or worsening.
Why Is LDN Often Compounded?
FDA-approved oral naltrexone is commonly available as a 50 mg tablet. A prescriber considering low-dose therapy may require a patient-specific strength or dosage form that is not commercially available.
A compounding pharmacy can prepare an individualized prescription when clinically appropriate and authorized by a licensed prescriber.
Pharmacist support can help with:
- Reviewing the prescription
- Screening for potential opioid conflicts
- Confirming the prescribed strength and dosage form
- Explaining storage and administration instructions
- Coordinating questions with the prescriber
- Supporting refill continuity
- Reinforcing medication-safety information
A compounded medication is not FDA-approved. The FDA does not review a compounded preparation for safety, effectiveness, or quality before it is marketed. Compounding can nevertheless serve an important patient-specific need when an FDA-approved product does not meet that need.
Read the FDA’s information about compounded medications.
Seven Questions to Ask Before Considering LDN
Use these questions during a consultation:
- What condition or symptom are we trying to address?
- How strong is the evidence for LDN in my specific condition?
- Do any of my medications contain an opioid?
- Could LDN interfere with surgery or emergency pain treatment?
- What side effects should I monitor?
- How will we determine whether treatment is helping?
- When should we reassess or discontinue treatment?
A trustworthy treatment process should be able to answer these questions without promising a particular result.
Is LDN Right for You?
LDN may be worth discussing if you have fibromyalgia, centralized pain, or another persistent pain condition and want to explore whether an off-label treatment fits your care plan.
But the decision should be based on:
- Your diagnosed condition
- The quality of supporting evidence
- Your complete medication list
- Your history of opioid exposure
- Your overall health
- Your treatment goals
- A licensed clinician’s independent judgment
LDN should not be treated as a universal anti-inflammatory supplement or a guaranteed solution for chronic symptoms.
Take the Next Step With Scripx Pharmacy
Scripx Pharmacy supports individualized compounded prescriptions and pharmacist-guided medication education.
If you are interested in LDN, the next step is to complete an appropriate clinical evaluation. A licensed medical provider will review your health history, current medications, treatment goals, and state eligibility before determining whether a prescription is appropriate.
Start your LDN consultation: [Insert LDN telehealth link]
Completing an assessment does not guarantee treatment or a prescription. Telehealth availability and pharmacy service depend on the patient’s state and applicable requirements.
You may also contact Scripx Pharmacy with questions about prescription requirements and compounded-medication support:
Scripx Pharmacy
601 W. FM 544, Suite 102
Murphy, TX 75094
Phone: 469-596-0341
Fax: 469-596-0412
This article is provided for general education and does not replace individualized medical advice. The LDN uses discussed are off-label. Compounded medications are not FDA-approved.
Frequently Asked Questions
Is LDN a pain medication?
LDN is not an opioid pain medication. Naltrexone is an opioid antagonist, meaning it blocks opioid receptors. LDN is prescribed off-label by some clinicians for selected chronic pain conditions, but it is not FDA-approved as a chronic pain treatment.
Is LDN proven to treat fibromyalgia?
Clinical studies and reviews suggest possible pain improvement for some patients, but results are mixed and available trials remain relatively small. LDN has not been proven to work for every person with fibromyalgia.
Can LDN reduce inflammation?
LDN is being studied for possible effects on inflammatory and neuroimmune pathways. Evidence does not support describing it as a universal treatment or cure for inflammation.
Can I take LDN while using an opioid?
Naltrexone can block opioid effects and precipitate withdrawal in an opioid-dependent person. Do not start LDN, stop an opioid, or transition between the two without direct guidance from a qualified clinician.
How quickly does LDN work?
There is no single response timeline. The underlying condition, individual response, treatment duration, other therapies, and method used to measure improvement can all affect the evaluation.
Why would a clinician prescribe compounded LDN?
A clinician may need a patient-specific strength or dosage form not available as an FDA-approved commercial product. The completed compounded preparation is not FDA-approved and requires a valid prescription.